Assessment For Retreatment with TACE (ART) Score

Assessment for Retreatment with TACE (ART) Score is an assessment tool used to determine the suitability of retreatment with trans-arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Patient with a score of 2.5 or more prior to Re TACE may not benefit from the procedure. 

ART score was developed using the radiologic EASL-response criteria (PR = greater than 50% tumor reduction) rather than mRECIST criteria (PR = greater than 30% tumor reduction). ¹

ParametersPoints
Absence of radiological response1 Point
AST (aspartate aminotransferase) increase > 25%4 Points
Child-Pugh Score increase by:
1 Point
2 Points
1.5 Points
3 Points
Total0-1.5 = Excellent Prognosis after Re TACE
≥ 2.5 = Dismal Prognosis after Re TACE
  1. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, Müller C, Heinzl H, Trauner M, Peck‐Radosavljevic M. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology. 2013 Jun;57(6):2261-73.
  2. Karademir S. Staging of hepatocellular carcinoma. Hepatoma Res. 2018;4:58.
  3. Kinoshita, Akiyoshi et al. “Staging systems for hepatocellular carcinoma: Current status and future perspectives.” World journal of hepatology vol. 7,3 (2015): 406-24. doi:10.4254/wjh.v7.i3.406
  4. Subramaniam, Somasundaram et al. “A review of hepatocellular carcinoma (HCC) staging systems.” Chinese clinical oncology vol. 2,4 (2013): 33. doi:10.3978/j.issn.2304-3865.2013.07.05
Skip to content